According to a research abstract by a team of scientists at Purdue, after the reformulation, sales of 80-milligram OxyContin pills dropped 25 percent nationwide. On the one hand, this was an impressive metric of Purdue’s success in curbing abuse of OxyContin by developing the new crushproof pills, and the company would tout the investment it made in the reformulation as evidence of its efforts to address the opioid crisis. On the other hand, that drop in sales offered a stark indication that for years Purdue had been deriving a quarter of its revenue on the highest dose of OxyContin from the
...more
